Traduction de «available that allow the clinical identification » (Néerlandais → Français) :

Even though there now are classifications available that allow the clinical identification of different types of depression, it still remains a fact that it is difficult to recognise one in care practice, especially in primary health care, with there being numerous ways in which this pathology can present itself (masked depression, depression that manifests itself through diffuse and persistent somatic signs…).
S’il existe aujourd’hui des classifications permettant d’identifier les différents types de dépression sur le plan clinique, il n’en reste pas moins vrai qu’en pratique de soin et en particulier en première ligne, des repérages restent difficiles au vu des travestissements de cette pathologie (dépression masquée, dépression se manifestant par des signes somatiques diffus et persistants…).

Committee is primarily concerned with the ethical and medical aspects, and is the body that has to provide explicit authorisation to allow a clinical trial to start.
Committee is primarily concerned with the ethical and medical aspects, and is the body that has to provide explicit authorisation to allow a clinical trial to start.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Other techniques that demonstrate mecA might become available in Belgium in the future (Evigene / Staten Serum Institute; Velogene rapid MRSA identification assay / ID Biomedical Corp).
D'autres techniques mettant en évidence le mecA pourraient devenir disponibles en Belgique dans le futur (Evigene / Staten Serum Institute; Velogene rapid MRSA identification assay / ID Biomedical Corp.).